HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

A73025

has heparin-like activity

Also Known As:

A 73025; A-73025; Adequan; PSGAG; glycosaminoglycan polysulfate; glycosaminoglycan polysulfuric acid ester; glycosaminoglycan polysulphate; polysulfated glycosaminoglycan; sulfated glycosaminoglycan

Networked: 105 relevant articles (6 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 4088
- Polysaccharides: 2929
  - Glycosaminoglycans: 2808
    - A73025: 105

Experts

1.	Frisbie, David D: 3 articles (06/2011 - 02/2009)
2.	McIlwraith, C Wayne: 3 articles (06/2011 - 02/2009)
3.	Liu, Hao: 2 articles (08/2014 - 03/2011)
4.	Feng, Ganjun: 2 articles (08/2014 - 03/2011)
5.	Kawcak, Chris E: 2 articles (06/2011 - 02/2009)
6.	Sayegh, Eli T: 1 article (03/2015)
7.	Strauch, Robert J: 1 article (03/2015)
8.	Takakura, Kazuki: 1 article (01/2015)
9.	Misawa, Takeyuki: 1 article (01/2015)
10.	Homma, Sadamu: 1 article (01/2015)

Related Diseases

1.	Osteoarthritis 03/01/1989 - "Clinical efficacy of glycosaminoglycan polysulfate for the treatment of osteoarthritis of the knee joint: a double blind controlled study." 09/01/1982 - "In order to evaluate the clinical efficacy of glycosaminoglycan polysulfate (GAGPS) in osteoarthrosis of the knee, a double blind comparative study was carried out at 26 orthopaedic clinics throughout Japan. " 01/01/1983 - "This study indicates that glycosaminoglycan polysulphate may inhibit the development of osteoarthritis." 02/01/2009 - "Induced osteoarthritis caused a substantial change in lameness, response to flexion, joint effusion, and radiographic findings, and of these, synovial fluid effusion was reduced with PSGAG, compared with control horses. " 06/01/2008 - "To analyze the presence of inflammatory cells in the synovial fluid (SF) of subjects with osteoarthritis (OA) and correlate them with the concentration of sulfated glycosaminoglycan (GAG). "
2.	Joint Diseases (Joint Disease) 11/01/1996 - "Use of PSGAG is regarded as moderately effective overall and is considered most useful in the treatment of subacute degenerative joint disease. " 11/01/1996 - "Use of PSGAG was reported to be moderately effective in the treatment of the 4 joint disease conditions. " 05/01/1990 - "Nonetheless, these observations provide direct evidence of a truly chondroprotective role for low molecular weight PSGAG in the treatment of equine degenerative joint disease." 11/01/1996 - "Information was obtained on frequency and route of administration of PSGAG for the treatment of each of 4 forms of degenerative joint disease, the efficacy of PSGAG, and its efficacy compared with that of sodium hyaluronate. " 10/01/1981 - "Arteparon, a polysulfated glycosaminoglycan, has been used in Europe for two decades in the treatment of degeneration joint disease and is currently being tested in this country. "
3.	Pain (Aches) 01/01/1988 - "The glycosaminoglycan polysulphate treatment brought about a significant reduction of pain (p less than 0.01) and improvement of joint mobility (p less than 0.001). " 06/28/1984 - "Glucosamine had a superior effect, in particular in mild arthritis, achieving an improvement of pain in 90%, while glycosaminoglycan polysulphate was successful in advanced cases. " 11/01/2011 - "In trials of injections of sclerosant, platelet-rich plasma, proteinase, glycosaminoglycan polysulfate, sodium hyaluronate, prolotherapy, and botulinum toxin compared with placebo injection or other therapies, only sodium hyaluronate compared with placebo showed consistently better results in the short and long term in overall improvement and pain reduction of lateral epicondylalgia (1 study). " 03/01/2011 - "Treatment with chondroprotective supplements (that is, glucosamine chondroitin, polysulfated glycosaminoglycan) and intraarticular corticosteroid injections (that is, methylprednisolone, ketorolac), together with pain management (that is, celecoxib, tramadol, carprofen), resulted in increased activity levels and decreased clinical signs of disease. "
4.	Synovitis 11/01/1996 - "Use of PSGAG was considered more effective than sodium hyaluronate for the treatment of subacute degenerative joint disease and less effective for idiopathic joint effusion and acute synovitis. "
5.	Body Weight (Weight, Body) 05/01/1985 - "Drug treatment of these rats with twice weekly subcutaneous doses of 1.0 mg, 2.0 mg or 5.0 mg glycosaminoglycan polysulphate = GAGPS (Arteparon) per kg body weight caused a pronounced and in many cases highly significant reduction of the intensity of experimental osteoarthrosis within the first 9 weeks. "

Related Drugs and Biologics

1.	A73025
2.	Arteparon
3.	Hyaluronic Acid (Hyaluronan)
4.	Glycosaminoglycans
5.	Botulinum Toxins (Botulinum Toxin)
6.	Collagenases (Collagenase)
7.	Peptide Hydrolases (Proteases)
8.	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)
9.	diacetylrhein (diacerein)
10.	A-factor (Streptomyces)

Related Therapies and Procedures

1.	Injections
2.	Intra-Articular Injections
3.	Viscosupplementation
4.	Laser Therapy (Surgery, Laser)
5.	Musculoskeletal Manipulations (Manipulative Therapy)